// App-Quantinova.ai

1969 : MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Paul G. Richardson

Principal Investigators

  • Craig C Hofmeister

  • David S Siegel

  • Ye Hua

  • Yan Li

  • Sheetal Shah

  • Jianming Wang

  • Kenneth C. Anderson

  • Sagar Lonial

  • Jacob P. Laubach

  • Yvonne A Efebera

  • David H. Vesole

  • Ajay K. Nooka

  • Jacalyn Rosenblatt

  • Noopur Raje

  • Mohamed H. Zaki

Medical Centers

  • Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Division of BMT, Winship Cancer Institute - Hematology and Medical Oncology, Emory University, Atlanta, GA

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic pancreatic adenocarcinoma

  • Peripheral neuropathy

  • Deep vein thrombosis

  • Pancreatic cancer

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Transthyretin

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

  • Aspirin

  • Albyl-E

  • Heparin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved